Sign In
Buy ABBV
$217.07
+1.64 (+0.761%)
At Close: Jun 03, 2026
Breakfast News: Trading Revenue Lifts JPMorgan
07:30am, Tuesday, 13'th Jan 2026
Banks begin to roll out earnings, AbbVie gets tariff exemption, UBS CEO set to depart, and more
AbbVie reaches 3-year deal with White House to lower drug prices
07:22am, Tuesday, 13'th Jan 2026
CNBC's Andrew Ross Sorkin reports on the latest news.
AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.
05:24am, Tuesday, 13'th Jan 2026
The pharma company has agreed to cut some prices in exchange for an exemption from some levies.
AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices
07:03pm, Monday, 12'th Jan 2026
As part of the three-year deal, the Trump administration exempted AbbVie from tariffs and future pricing mandates, the company said.
Abbvie, US reach agreement to cut drug prices
06:57pm, Monday, 12'th Jan 2026
Abbvie reached a three-year agreement with U.S. President Donald Trump's administration to provide low prices in Medicaid through TrumpRx, and pledged $100 billion over the next decade for research an
AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
06:30pm, Monday, 12'th Jan 2026
AbbVie will provide low prices in Medicaid, and expand affordable, direct-to-patient offerings for treatments used by millions of Americans through TrumpRx AbbVie will commit $100 billion in U.S. rese
AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense
09:55am, Monday, 12'th Jan 2026
ABBV stock falls 3% in a month amid takeover rumor denials, but Skyrizi and Rinvoq momentum and a deep pipeline support staying invested.
AbbVie, RemeGen partner on experimental solid tumor treatment
07:39am, Monday, 12'th Jan 2026
AbbVie said on Monday it would partner with RemeGen to develop an experimental treatment for solid tumors in a deal worth up to $4.95 billion, including milestones.
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
07:30am, Monday, 12'th Jan 2026
- RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancers NORTH CHICAGO, Ill. and YANTAI, China, Jan. 12, 2026 /PRNe
West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie
06:00am, Monday, 12'th Jan 2026
EXTON, Pa., Jan. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the company h
AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
06:00am, Monday, 12'th Jan 2026
Milestone marks progress against AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. over the next decade to broadly support innovation and expand critical
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
05:47am, Monday, 12'th Jan 2026
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
3 No-Brainer Dividend Stocks to Buy Right Now
03:45am, Monday, 12'th Jan 2026
AbbVie is a Dividend King in growth mode. Enbridge offers an attractive dividend plus both safety and growth potential.
MoneyShow's Best Investment Ideas For 2026: Part 1
09:30am, Saturday, 10'th Jan 2026
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, an
2 Healthcare Stocks That Can Diversify a Tech-Heavy Portfolio
11:45am, Friday, 09'th Jan 2026
AbbVie and Johnson & Johnson have resilient, noncyclical businesses. They are also outstanding dividend payers.
